(CANC) Tema Oncology - Ratings and Ratios
Biotech, Pharma, Diagnostics, Equipment
Description: CANC Tema Oncology November 02, 2025
The Tema Oncology ETF (NASDAQ:CANC) is a U.S.-based, health-sector ETF that commits at least 80% of its net assets-including any investment-purpose borrowings-to publicly listed companies deriving 50% or more of their revenue from oncology, and it operates as a non-diversified fund.
Key industry metrics reinforce the fund’s focus: the global oncology market, valued at roughly $280 billion in 2023, is projected to grow at a compound annual growth rate of about 8% and exceed $400 billion by 2030, driven largely by rapid adoption of immunotherapies, CAR-T cell treatments, and precision medicine. The ETF’s expense ratio sits near 0.70%, and its top holdings typically include major oncology players such as Bristol-Myers Squibb, Merck & Co., and Roche, which together account for a substantial share of the portfolio’s exposure.
For a deeper quantitative breakdown of CANC’s exposure and risk profile, you might find the analytics on ValueRay worth a look.
CANC ETF Overview
| Market Cap in USD | 85m |
| Category | Health |
| TER | 0.75% |
| IPO / Inception | 2023-08-14 |
CANC ETF Ratings
| Growth Rating | 63.0% |
| Fundamental | - |
| Dividend Rating | 58.2% |
| Return 12m vs S&P 500 | -5.07% |
| Analyst Rating | - |
CANC Dividends
| Dividend Yield 12m | 2.35% |
| Yield on Cost 5y | 20.68% |
| Annual Growth 5y | 388.59% |
| Payout Consistency | 100.0% |
| Payout Ratio | % |
CANC Growth Ratios
| Growth Correlation 3m | 95.1% |
| Growth Correlation 12m | 38.6% |
| Growth Correlation 5y | 31.6% |
| CAGR 5y | 167.47% |
| CAGR/Max DD 3y (Calmar Ratio) | 5.97 |
| CAGR/Mean DD 3y (Pain Ratio) | 20.62 |
| Sharpe Ratio 12m | 0.19 |
| Alpha | -2.57 |
| Beta | 0.000 |
| Volatility | 22.33% |
| Current Volume | 2.8k |
| Average Volume 20d | 6k |
| Stop Loss | 30 (-3.2%) |
| Signal | 0.57 |
What is the price of CANC shares?
Over the past week, the price has changed by +3.12%, over one month by +7.94%, over three months by +19.61% and over the past year by +15.25%.
Is Tema Oncology a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CANC is around 32.66 USD . This means that CANC is currently overvalued and has a potential downside of 5.42%.
Is CANC a buy, sell or hold?
What are the forecasts/targets for the CANC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 36.6 | 18.3% |
CANC Fundamental Data Overview November 01, 2025
Beta = 0.0
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 85.5m USD (85.5m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 85.5m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 85.5m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.16% (E(85.5m)/V(85.5m) * Re(9.16%) + (debt-free company))
Discount Rate = 9.16% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for CANC ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle